Online citations, reference lists, and bibliographies.

Drug Sensitivity-related Benefit Of Systematic Lymphadenectomy During Cytoreductive Surgery In Optimally Debulked Stages IIIc And IV Ovarian Cancer.

S. Isonishi, S. Niimi, H. Sasaki, K. Ochiai, M. Yasuda, T. Tanaka
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVE The purpose of this study is to assess the survival experience following systematic lymphadenectomy (LNX) in conjunction with primary but optimal cytoreductive surgery in advanced epithelial ovarian cancer (OC) patients when followed by intensive chemotherapy. METHODS This is a retrospective analysis of all women with OC who were treated in our institution between 1992 and 2000. A total of 98 patients with stages IIIc-IV of OC underwent primary cytoreductive surgery which was 'optimal' (<1 cm residual disease). All patients subsequently received postoperative platinum-containing chemotherapy. Group I, consisting of 51 patients underwent LNX; Group II, consisting of 47 patients did not undergo LNX. The percentage of patients failing to respond to chemotherapy in each group was similar. Each group had statistically equivalent age, stage, regimens of chemotherapy performed, and all other known prognostic factors. RESULTS No survival benefit could be seen in platinum-sensitive patients. However, in patients who failed to respond to chemotherapy, the 2-year progression-free survival (PFS) (42.8% vs. 14.3%) and overall survival (OS) (51.2% vs. 28.8%) was quite different. LNX significantly improved those of drug-resistant patients when optimal cytoreductive surgery was performed [P = 0.008, risk ratio (rr) = 2.675, 95% confidence interval (CI) = 1.251-5.724]. Cox's proportional analysis shows that LNX was one of the three most significant covariate with the tumor grade and the number of postoperative residual lesions. CONCLUSIONS The results show that LNX might be of benefit in patients who have optimal primary cytoreductive surgery and who do not respond to platinum-based chemotherapy.
This paper references
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity.
A. Heintz (1986)
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W. Mcguire (1996)
Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival.
C. Scarabelli (1995)
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
G. Rustin (1996)
Advanced ovarian cancer. Dose intensity.
R. Ozols (1993)
Pelvic lymphadenectomy in operative treatment of ovarian cancer
E. Burghardt (1986)
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
J. Shapiro (1998)
Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium
F. Di Re (2000)
Advanced ovarian cancer
M. V. D. Burg (2001)
Surgical staging and cytoreductive surgery of epithelial ovarian cancer
W. Hoskins (1993)
Management of Advanced Ovarian Cancer
E. Burghardt (1980)
WHO Handbook for Reporting Results of Cancer Treatment
R. Hunter (1980)

This paper is referenced by
The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy
Kyung Jin Eoh (2017)
Les curages lymphatiques dans les cancers de l'ovaire.Commentaire
Richard Villet (2010)
The Role of Lymphadenectomy in Node-Positive Epithelial Ovarian Cancer
A. Pereira (2012)
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
Die Rolle der radikalen Lymphadenektomie
P. Wimberger (2008)
Erkrankungen der Adnexe
Julia Gallwas (2018)
The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer.
A. Abe (2010)
[The role of radical lymphadenectomy. Experiences from the AGO Ovarian Cancer Study Group].
Pauline Wimberger (2009)
Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer
P. Harter (2006)
Prognostic Significance of Systematic Lymphadenectomy in Patients With Optimally Debulked Advanced Ovarian Cancer: A Meta-Analysis
Yizi Wang (2020)
The role systematic lymphadenectomy plays in determining the survival outcome for advanced ovarian cancer patients: a meta- analysis.
Dan Xu (2020)
Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved.
S. Chambers (2005)
Contre le curage lomboaortique systmatique dans la prise en charge des cancers de lovaire
R. Villet (2007)
Leczenie chirurgiczne w zaawansowanym raku jajnika
Łukasz Wicherek (2012)
Systematic Lymphadenectomy for Survival in Epithelial Ovarian Cancer: A Meta-Analysis
H. S. Kim (2010)
EORTC-GCG process quality indicators for ovarian cancer surgery.
L. Verleye (2009)
Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery
Kyung Jin Eoh (2017)
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
P. Panici (2005)
Semantic Scholar Logo Some data provided by SemanticScholar